Skip to content

Inspection Record

Biotest AG — FDA 483 Findings

US FDAInspected 2023-12-15Published 2026-10-26 9 findingsProcess validationDeviation, CAPA, and investigationEquipment and facilityOther quality systemMaterial and supplier control

View the regulator's official source The source document is always the basis for judgement.

Findings

1Process validation

Process controls are not established from validated manufacturing processes.

2Deviation, CAPA, and investigation

Deviation management is inadequate to demonstrate quality oversight of the manufacturing process, and does not adequately identify, document, or investigate the impact to drug product.

3Equipment and facility

Manufacturing building™®, where the Yimmugo drug product is manufactured, does not contain sufficient space to prevent mix-ups and to secure the product.

4Other quality system

The (6)(4) sampling process for routinely monitoring the (b) (4) is deficient.

5Material and supplier control

Strict control is not exercised over labeling materials issued for use in the Yimmugo drug product labeling operations.

6Equipment and facility

Manufacturing buildings used in the manufacture ofYimmugo do not have the suitable controls to prevent contamination.

7Other quality system

Inadequate quality oversight to assure that the Yimmugo drug product has the identity, strength, quality, and purity it purports or is represented to possess.

8Other quality system

The manual visual inspection program is inadequate to identify))(b) (4) matter and physical defects.

9Process validation

Process validation is deficient as it does not cover the proposed range for process parameters that are critical.

Similar findings at other companies

GRM selected findings from the same type of public document whose wording is close to a finding in this document. One per company.

A record as of the US FDA document published on 2026-10-26. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.

Biotest AG company profile — full historyAll US FDA findings US FDA documents, 2026 Go to Findings search
Linked from (backlinks)
Briefs that featured this document
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.